Editorials |
From the Department of Biochemistry and Integrative Medical Biology, School of Medicine, Keio University, Tokyo, Japan.
Correspondence to Takeshi Adachi, MD, PhD, Department of Biochemistry and Integrative Medical Biology, School of Medicine, Keio University, Research Park 4N8, 35 Shinanomachi Shinjuku-ku, Tokyo Japan 160-8582. E-mail tadachi{at}sc.itc.keio.ac.jp
See related article, pages 985–994
Key Words: Ets-1 NAD(P)H oxidase Angiotensin II hypertension
| Introduction |
|---|
|
|
|---|
In this issue of Circulation Research, Ni and colleagues identified that Ets-1 was a critical transcriptional regulator of p47phox induced by Ang II in vitro and in vivo.6 Ets-1 has been known as a proto-oncogene transcription factor to induce matrix-degradation proteins such as collagenase, plasminogen activation inhibitor-1(PAI-1), and matrix-metalloproteinases. Ets-1 can be induced by TNF-
, endothelin-1, prostanoid(s), and platelet-derived growth factor,7–8 suggesting an implication in vascular inflammation. Indeed, this group previously reported that Ets-1 was a critical factor needed to induce cyclin-dependent kinase, PAI-I, vascular cells adhesion molecule-1, and monocyte chemoattractant protein-1 in response to Ang II. In Ets-1–/– mice, the vascular inflammation by Ang II infusion, which was represented by the recruitment of T cell and macrophage to vessel wall, was blunted, although hypertensive response was preserved.9 In this article, the authors carefully seek the molecular mechanisms to regulate the expression of NAD(P)H oxidase subunits by Ets-1. The augmentation of superoxide and hydrogen peroxide (H2O2) generations by Ang II were markedly attenuated in aorta from Ets-1–/– mice or VSMCs with siRNA for Ets-1. siRNA for Ets-1 also blunted the upregulation of p47phox without affecting the expression of Nox1, Nox4, Rac1, p22phox, and p67phox by Ang II. They used gel-shift assay, luciferase reporter assay, and chromatin immunoprecipitation assay with deletion mutant of p47phox promoter, and identified the –45 Ets-1–binding promoter region as essential for the induction of p47phox. They developed peptides to inhibit ETS-1 bindings (DN-Ets-1 peptides) and delivered them to the Ang II–infused mice in vivo. DN-Ets-1 peptides attenuated medial hypertrophy and aortic ROS generation without affecting hypertensive response to Ang II.
This article impacts the field of hypertension research in 3 major ways. First, the authors demonstrate the importance of p47phox induction for aortic ROS generation in Ang II–induced hypertension. p47phox is phosphorylated at S359/S370/S379 by PKC, which causes association with p22phox. S303/S304 of p47phox were also phosphorylated to augment the catalytic activity of NAD(P)H oxidase.4 We expressed S303A/S304A mutant p47phox in VSMCs to suppress the redox-sensitive signal by Ang II.10 The posttranslational modifications of p47phox by Ang II are critical for the rapid activation of NAD(P)H oxidase.
The importance of p47phox expression in Ang II–induced hypertension was also shown by Landmesser and colleagues.11 An increase in superoxide generation of aorta by Ang II was blunted in p47phox–/– mice but rose 3-fold in control. Hypertensive response to Ang II was modestly decreased in p47phox–/– mice. Consistent with these observations and the results by Ni and colleagues,6 p47phox induction is essential for aortic ROS generation and vascular inflammation in Ang II-infusion, whereas it is not required for the hypertensive response. Because Ets-1 is a critical transcriptional regulator for p47phox, it is a potential therapeutic target for vascular inflammation.
Second, this study showed the importance of transcriptional regulation of the NAD(P)H oxidase. The authors clearly show the specific induction of p47phox by Ets-1 without affecting the expressions of other subunits by Ang II. AP-1 was shown to regulate the expression of p67phox in monoytes,12 however, vascular NAD(P)H oxidase may contain an alternative to p67phox subunit, NoxA1,4 and the transcriptional regulation of vascular NAD(P)H oxidases are largely unknown. Stimulation of VSMCs with Ang II activates many of early genes, including AP-1 (c-fos, c-jun), NF-
ß(p50, p65), ATF/CREB, hypoxia-inducible factor-1 (HIF-1), Egr-1, STAT1, and Nrf-2.1,13 Wilson et al14 showed that H2O2 upregulated translations of Ets-1, which were mediated by the activation of Nrf-2/ARE (antioxidant response element). It is possible that the rapid activation of NADPH oxidase causes the expression of Ets-1 by redox-sensitive mechanism, which in turn induces p47phox for the booster effects of ROS generation by Ang II.
| Redox-Sensitive Thiols Can Be Critical Targets for NAD(P)H Oxidase |
|---|
|
|
|---|
ß activation.20 ROS oxidizes the reactive thiol on Keap1 to dissociate Nrf-2, leading to the Nrf-2-transcription. In contrast, many transcription factors such as AP-1 and NF-
ß have redox-sensitive thiols in the DNA-binding sites and their modifications disturb DNA binding. The effects of ROS on transcription may differ according to the localization of ROS.13 | Targeting NAD(P)H Oxidase for Vascular Diseases |
|---|
|
|
|---|
|
| Acknowledgments |
|---|
The work was supported by Grants-in-Aid for Scientific Research (B:19390090) (to T.A.) and for Creative Scientific Research 17GS0419 (to T.A. and M.S.). T.A. and M.S. are core members of Global Center-of-Excellence (GCOE) for Human Metabolomics Systems Biology from MEXT. M.Y. is a research fellow supported by New Energy and Industrial Technology Development Organization.
Disclosures
None.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, Suematsu M, Zweifach BW, Schmid-Schoenbein GW. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci U S A. 1998; 95: 4754–4759.
3. Griendling KK, Minieri CA, Ollerenshaw JD, Alxander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994; 74: 1141–1148.
4. Lyle AN, Griendling KK. Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology. 2006; 21: 269–280.
5. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL. Expression of a functional active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res. 2002; 90: 1205–1213.
6. Ni W, Zhan Y, He H, Maynard E, Balschi JA, Oettgen P. Est-1 is a critical transcriptional regulator of reactive oxygen species and p47phox gene expression in response to angiotensin II. Circ Res. 2007; 101: 985–994.
7. Naito S, Shimizu S, Maeda S, Wang J, Paul R, Fagin JA. Ets-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells. Am J Physiol. 1998; 274: C472–C480.[Medline] [Order article via Infotrieve]
8. Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, Ashley SW, Whang EE. Prostagrandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependnet induction of matrix metalloproteinase-2. Cancer Res. 2004; 64: 7439–7446.
9. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest. 2005; 115: 2508–2516.[CrossRef][Medline] [Order article via Infotrieve]
10. Adachi T, Pimentel DR, Heibeck T, Hou X, Lee YJ, Jiang B, Ido Y, Cohen RA. S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells. J Biol Chem. 2004; 279: 29857–29862.
11. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG. Role of p47phox in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension. 2002; 40: 511–515.
12. Gauss KA, Bunger PL, Quinn MT. Ap-1 is essential for p67(phox) promotor activity. J Leuckoc Biol. 2002; 71: 163–172.
13. Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional Regulation. Circ Res. 2005; 97: 967–974.
14. Wilson LA, Gemin A, Espiritu R, Singh G. ets-1 is transcriptionally up-regulated by H2O2 via an antioxidant response element. FASEB. J. 2005; 19: 2085–2087.
15. Adachi T, Schöneich C, Cohen RA. S-Glutathiolation in redox-sensitive signaling. Drug Discov Today. 2005; 2: 39–46.[CrossRef]
16. Rhee SG, Bae YS, Lee SR, Kwon J. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci STKE. 2000; 2000: PE1.
17. Heo J, Campbell SL. Mechanism of redox-mediated guanine nucleotide exchange on redox-activate Rho GTPase. J Biol Chem. 2005; 280: 31003–31010.
18. Pan S, Berk BC. Glutathiolation regulates tumor necrosis factor-alpha-induced caspase-3 cleavage and apoptosis: key role for glutaredoxin in the death pathway. Circ Res. 2007; 100: 213–219.
19. Janiszewski M, Lopes LR, Carmo AO, Pedro MA, Brandes RP, Santos CX, Laurindo FR. Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells. J Biol Chem. 2005; 280: 40813–40819.
20. Reynaert NL, van der Vliet A, Guala AS, McGovern T, Hristova M, Pantano C, Heintz NH, Heim J, Ho YS, Matthews DE, Wouters EF, Janssen-Heininger YM. Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. Proc Natl Acad Sci U S A. 2006; 103: 13086–13091.
21. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O2– and systolic blood pressure in mice. Circ Res. 2001; 89: 408–414.
22. Ito M, Adachi T, Pimentel DR, Ido Y, Colucci WS. Statin inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocyte via a Rac1-dependent mechanism. Circulation. 2004; 110: 412–418.
23. Matsui R, Xu S, Maitland KA, Hayes A, Leopold JA, Handy DE, Loscalzo J, Cohen RA. Glucose-6 phosphate dehydrogenase deficiency decreases the vascular response to angiotensin II. Circulation. 2005; 112: 257–263.
Related Article:
Circ. Res. 2007 101: 985-994.
This article has been cited by other articles:
![]() |
W. J. Welch Angiotensin II-Dependent Superoxide: Effects on Hypertension and Vascular Dysfunction Hypertension, July 1, 2008; 52(1): 51 - 56. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |